argenx will attend the upcoming investor conference

[ad_1]

June 1, 2021

Breda, The Netherlands – Argenx ((Euronext and Nasdaq:ARGX), a global immunology company dedicated to improving the lives of patients with severe autoimmune diseases and cancer, today announced that management members will participate in the following upcoming investor meetings:

  • Goldman Sachs 42nd Annual global healthcare conference. Fireside chat on Tuesday, June 8, 2021 at 2:10 pm Eastern Time.
  • JMP Securities Life Science Conference. Chat on the fireside at 11 am EST on Wednesday, June 16, 2021.
  • JPMorgan Chase European Healthcare Conference. The management will attend the investor meeting on Thursday, June 17, 2021.
  • Raymond James Human Health Innovation Conference. The management will participate in the panel discussion on Tuesday, June 22, 2021 at 12 noon.

More information about these activities will be provided on the company website: www.argenx.com.

About argenx
argenx is a global immunology company dedicated to improving the lives of people with severe autoimmune diseases and cancer. argenx collaborates with leading academic researchers through its Immunology Innovation Program (IIP) to transform immunological breakthroughs into a world-class portfolio of new antibody drugs. argenx is working with Janssen to evaluate the efficacy of efgartigimod in a variety of severe autoimmune diseases and the efficacy of cusatuzumab in blood cancers. argenx is also advancing several early-stage experimental drugs within its therapeutic franchise. argenx has offices in Belgium, the United States, Japan and Switzerland.For more information, please visit https://www.argenx.com/ And follow us on LinkedIn https://www.linkedin.com/company/argenx/ And twitter https://twitter.com/argenxglobal.

For more information, please contact:

media:

Kelsey Kirk
kkirk@argenx.com

joke
jcomijn@argenx.com

investor:

Beth Deljaco
bdelgiacco@argenx.com

Michelle Greenblatt
mgreenblatt@argenx.com

Main logo



[ad_2]

Source link

Recommended For You

About the Author: News Center